90
Participants
Start Date
November 27, 2023
Primary Completion Date
January 31, 2025
Study Completion Date
December 31, 2027
Capecitabine
1000 mg/m2, Bid orally, D1-14, every 3 weeks
oxaliplatin
130 mg/m2, intravenous infusion, D1, every 3 weeks
Disitamab Vedotin
2.5 mg/kg, intravenous infusion, D1, every 2 weeks
Toripalimab
3.0 mg/kg, intravenous infusion, D1, every 2 weeks
RECRUITING
Beijing Cancer Hospital, Beijing
NOT_YET_RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Kunming
NOT_YET_RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
NOT_YET_RECRUITING
Gansu Wuwei Tumour Hospital, Wuwei
NOT_YET_RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
NOT_YET_RECRUITING
Nanfang Hospital, Guangzhou
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Shandong Cancer Hospital & Institute, Jinan
NOT_YET_RECRUITING
Sichuan Cancer Hospital & Institute, Chengdu
RemeGen Co., Ltd.
INDUSTRY